[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100411535":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":81,"centralContacts":85,"locations":95,"responsibleParty":147,"collaborators":89,"id":149,"slug":150,"hasResults":151,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":151,"sex":157,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":89,"studyType":163,"phases":164,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":98,"whyStopped":89,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},{"fullName":5,"class":6},"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia","OTHER",[8,17,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Early favorable HL","EXPERIMENTAL","HL without adverse prognostic factors",[13,14,15,16],"Drug: Doxorubicin","Drug: Bleomycin","Drug: Vinblastine","Drug: Dacarbazine",{"label":18,"type":10,"description":19,"interventionNames":20},"Early unfavorable HL","Early unfavorable (stages IA-B, IIA bulky and\u002For extranodal lesions, age less than 50 years)",[13,15,16,21,22,23,24],"Drug: Etoposide","Drug: Cyclophosphamide","Drug: Vincristine","Drug: Dexamethasone",{"label":26,"type":10,"description":27,"interventionNames":28},"Advanced stages HL","(age less than 50 years)",[21,13,22,23,24,16],[30,37,42,47,52,58,62,67,72,77],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DRUG","Doxorubicin","25 mg\u002Fm2 i.v. day 1,15 for ABVD\u002FAVD",[9,18],[36],"ABVD",{"type":31,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"Bleomycin","10,000 units\u002Fm2 i.v. days 1,15 for ABVD",[9],[36],{"type":31,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"Vinblastine","6 mg\u002Fm2 i.v. days 1,15 for ABVD\u002FAVD",[9,18],[36],{"type":31,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"Dacarbazine","375 mg\u002Fm2 i.v. days 1,15 for ABVD\u002FAVD",[9,18],[36],{"type":31,"name":53,"description":54,"armGroupLabels":55,"otherNames":56},"Etoposide","100 mg\u002Fm2 i.v. days 1-3",[26,18],[57],"EACODD-14",{"type":31,"name":32,"description":59,"armGroupLabels":60,"otherNames":61},"50 mg\u002Fm2 i.v. day 1 for EACODD-14",[26,18],[57],{"type":31,"name":63,"description":64,"armGroupLabels":65,"otherNames":66},"Cyclophosphamide","650 mg\u002Fm2 i.v. day 1",[26,18],[57],{"type":31,"name":68,"description":69,"armGroupLabels":70,"otherNames":71},"Vincristine","1,4 mg\u002Fm2 i.v. day 8",[26,18],[57],{"type":31,"name":73,"description":74,"armGroupLabels":75,"otherNames":76},"Dexamethasone","20 mg i.v. days 1-3",[26,18],[57],{"type":31,"name":48,"description":78,"armGroupLabels":79,"otherNames":80},"375 mg\u002Fm2 i.v. day 1 for EACODD-14",[26,18],[57],[82],{"name":83,"affiliation":5,"role":84},"Vladislav Sarzhevskiy, PhD","PRINCIPAL_INVESTIGATOR",[86,91],{"name":83,"role":87,"phone":88,"phoneExt":89,"email":90},"CONTACT","+7-910-436-00-40",null,"vladsar100@gmail.com",{"name":92,"role":87,"phone":93,"phoneExt":89,"email":94},"Nikita Mochkin, PhD","+7-910-456-87-06","nickmed@yandex.ru",[96,130],{"facility":97,"status":98,"city":99,"state":100,"zip":89,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":108,"contacts":109},"Tata Memorial Hospital","RECRUITING","Mumbai","Opd-81 Main Building, Dr. E Borges Road, Parel 400012","India","IN",{"type":104,"coordinates":105},"Point",[106,107],72.88261,19.07283,{"lat":107,"lon":106},[110,115,117,119,121,123,125,127,129],{"name":111,"role":87,"phone":112,"phoneExt":113,"email":114},"Hasmukh Jain, Dr.","02224177018","7718982948","dr.hkjain@gmail.com",{"name":116,"role":87,"phone":112,"phoneExt":113,"email":89},"Lingaraj Nayak, Dr.",{"name":118,"role":87,"phone":89,"phoneExt":89,"email":89},"Manju Sengar, Dr.",{"name":120,"role":87,"phone":89,"phoneExt":89,"email":89},"Bhausaheb Bagal, Dr.",{"name":122,"role":87,"phone":89,"phoneExt":89,"email":89},"Tanuja Shet, Dr.",{"name":124,"role":87,"phone":89,"phoneExt":89,"email":89},"Archi Agrawal, Dr.",{"name":126,"role":87,"phone":89,"phoneExt":89,"email":89},"Venkatesh Rangarajan, Dr.",{"name":128,"role":87,"phone":89,"phoneExt":89,"email":89},"Alok Shetty, Dr.",{"name":111,"role":87,"phone":89,"phoneExt":89,"email":89},{"facility":131,"status":98,"city":132,"state":89,"zip":133,"country":134,"countryCode":135,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation","Moscow","105203","Russia","RU",{"type":104,"coordinates":137},[138,139],37.61781,55.75204,{"lat":139,"lon":138},[142,145],{"name":143,"role":87,"phone":144,"phoneExt":89,"email":90},"Vladislav Sarzhevskiy, MD, PhD","+74956037217",{"name":146,"role":87,"phone":144,"phoneExt":89,"email":94},"Nikita Mochkin, MD, PhD",{"type":148,"investigatorFullName":89,"investigatorTitle":89,"investigatorAffiliation":89,"oldNameTitle":89,"oldOrganization":89},"SPONSOR","100411535","phase-3-first-line-chemotherapy-for-classical-hodgkin-lymphoma-in-russia-hl-russia-1-100411535",false,"NCT04638790","First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)","First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia","HL-Russia-1","Inclusion Criteria:\n\n* Histologically confirmed classical HL\n* Previously untreated disease\n* Age 18-5 years\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2\n* Adequate organ and marrow function as defined below: absolute neutrophil count \\>1,0 x109\u002FL, platelets \\>75 x109\u002FL\n* Total bilirubin \\\u003C2 mg\u002Fdl without a pattern consistent with Gilbert's syndrome\n* Creatinine within normal institutional limits or creatinine clearance \\>50 mL\u002Fmin\u002F1.73 m2\n* Females of childbearing must have a negative pregnancy test at medical supervision even if had been using effective contraception\n* Life expectancy \\> 6 months\n* Able to adhere to the study visit schedule and other protocol requirements\n* Sign (or their legally acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.\n* Access to PET-CT (positron emission computed tomography) scans facilities\n\nExclusion Criteria:\n\n* Nodular Lymphocyte Predominant HL\n* Prior chemotherapy or radiation therapy\n* Pregnant or lactating females\n* Cardiac arrhythmia, conduction abnormalities, ischemic cardiopathy, left ventricular hypertrophy or left ventricular ejection fraction (LVEF) ≤50% at echocardiography.\n* Abnormal QTc (corrected QT interval) interval prolonged (\\>450 msec in males; \\>470 msec in women)\n* Uncontrolled infectious disease\n* Human immunodeficiency virus (HIV) positivity or active infectious A, B or C hepatitis. HBsAg-negative patients with anti-HBc (hepatitis B core antigen) antibody and can be enrolled provided that Hepatitis B Virus (HBV)-DNA are negative and that antiviral treatment with nucleos(t)ide analogs is provided\n* Uncompensated diabetes\n* Refusal of adequate contraception\n* Any medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment.","ALL","18 Years","50 Years",{"count":161,"type":162},300,"ESTIMATED","INTERVENTIONAL",[165],"PHASE3","The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).",[168],"Hodgkin Lymphoma, Adult",[57],"2024-09-25",{"date":172,"type":173},"2024-09-27","ACTUAL",{"date":175,"type":173},"2020-02-01",{"date":177,"type":162},"2026-12-31",{"name":5,"class":6},2]